Research HER
Related Resources for this page:
- Clinical Trials
- Cancer Biomarkers
- Breast Cancer
- A brief history of ADCs
- Breast Cancer
- Current research in ADCs
- Cytotoxic agent
- Slide decks and videos
- HER2 dimerization
- How are ADCs designed to work?
- Glossary
- Monoclonal antibody
- Receptor-Mediated Endocytosis
- Research HDIs
- Research ADCs
- Slide decks and videos
- Stable linker
- Targeting cancers with ADCs
- HER2+ breast cancer
- Trastuzumab Emtansine (T-DM1)
- What are ADCs?
- Ovarian Cancer
- Breast Cancer
- Future Directions
Share
HER3 Receptor Overview
— Lee-Hoeflich ST et al, Cancer Res, 20081
The central role of HER3 signaling in HER2–amplified breast cancer suggests that HER3 is a promising therapeutic target.
HER3 is increasingly coming under investigation for its role in the development of cancer. This section of ResearchHERPathways.com focuses on the way HER3 may cause cancer cells to grow and spread in spite of currently available therapeutic agents, as well as its prognostic value and role in breast and ovarian cancers. Click on the links below to learn more.